Lakefront Biotherapeutics (LKFT) Raw Materials (2021 - 2025)

Lakefront Biotherapeutics (LKFT) has 5 years of Raw Materials data on file, last reported at $26.2 million in Q4 2025.

• Raw Materials for Q4 2025 came in at $26.2 million, down 52.14% year-over-year; the trailing twelve-month figure through Dec 2025 was $26.2 million (down 52.14% YoY), and the FY2025 annual result was $26.2 million, down 52.14% from the prior year.
• Raw Materials eased to $26.2 million in Q4 2025 per LKFT's latest filing, from $54.7 million in the prior quarter.
• Over five years, Raw Materials peaked at $59.5 million in Q4 2023 and troughed at $16.4 million in Q4 2021.
• A 5-year average of $39.3 million and a median of $39.9 million in 2022 frame the typical range for Raw Materials.
• The sharpest annual moves came in 2022 and 2025: Raw Materials soared 142.81% in 2022, then sank 52.14% in 2025.
• A 5-year view of Raw Materials shows it stood at $16.4 million in 2021, then soared by 142.81% to $39.9 million in 2022, then surged by 49.16% to $59.5 million in 2023, then retreated by 8.0% to $54.7 million in 2024, then slumped by 52.14% to $26.2 million in 2025.
• Business Quant data shows LKFT's Raw Materials at $26.2 million in Q4 2025, $54.7 million in Q4 2024, and $59.5 million in Q4 2023.